PubMed Health⌕ Search

Biomedical subjects

C Seyfried

Publications and source records attributed to C Seyfried.

10 recordsLinked to original sources

Effects of alpha-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate.

The hydroxyl radical is a very reactive oxygen species that damages biomolecules in the brain and in other tissues. The possible pharmacological intervention to prevent hydroxyl radical formation was studied in vivo using the microdialysis technique in brains of nonanesthetized rats. Hydroxyl radicals form stable adducts [mainly 2,3-dihydroxybenzoic acid (2,3-DHBA) and 2,5-DHBA)] via an aromatic hydroxylation reaction with salicylic acid. 2,3-DHBA was separated and quantified by HPLC and electrochemical detection. Microdialysis probes were implanted into the striatum 1 day before measurement of levels of hydroxyl radicals. The next day, the probes were first perfused for 120 min with a modified Ringer's solution containing 5 mM salicylic acid, to obtain stable baselines. Afterward, the perfusion solution was switched to another solution that in addition contained 50 mM glutamate, to stimulate radical formation. Twenty minutes later, alpha-phenyl-tert-butylnitrone (PBN; 100 mg/kg), selegiline (10 mg/kg), or saline was administered intraperitoneally. The glutamate perfusion produced marked two- to 2.5-fold increases in 2,3-DHBA content. Treatment with PBN significantly antagonized the rise of 2,3-DHBA level, indicating that PBN is a direct radical scavenger not only in vitro but also in vivo. Acute treatment with selegiline failed to reduce significantly the glutamate-induced radical formation. The acute experiments presented here do not support the suggestion that the neuroprotective effects of selegiline described in the literature are due to a potential hydroxyl radical scavenging property of the drug.

Administration, Topical↗

HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes.

We examined the association of individual HLA genes with rheumatoid arthritis (RA), using oligonucleotide probes that identified both DR4-associated and non-DR4-associated genes. Two distinct HLA-DR beta alleles (Dw4 and Dw14) were found in DR4+ RA patients compared with controls (Dw4 50% versus 17%; Dw14 35% versus 5%; total DR4 73% versus 30%), indicating that these 2 alleles are independent susceptibility genes. Remarkably, the majority of the DR4- RA patients also demonstrated a linear DNA sequence, apparently "shuffled" between different susceptibility alleles, identified with an oligonucleotide probe to a key portion of the Dw14 gene.

Adult↗

HLA class II typing using oligonucleotide probes.

A DQ beta locus-specific oligonucleotide probe is used to identify DQ beta alleles present in six insulin-dependent diabetes mellitus (IDDM) multiplex families. Results of genotyping using this technique agree with those from cDNA probes and are often clearer. Allele-specific oligonucleotide probes for the DR beta locus are used to identify subtypes (Dw4 and Dw14) of the DR4 specificity in five IDDM multiplex families. This distinction cannot be made with available cDNA probes.

Blotting, Southern↗

Studies on the receptor profile of bisoprolol.

The in vitro binding affinity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol hemifumarate (bisoprolol, EMD 33 512) to beta 1-, beta 2-, alpha 1-, alpha 2-, D1-, D2-, 5-HT2- and muscarinic cholinergic receptors of rat was compared with that of atenolol, betaxolol and propranolol. Bisoprolol showed a high specific binding affinity to beta 1-adrenoceptors (heart) and a low specific binding affinity to beta 2-adrenoceptors (lung). The beta 1-selectivity of bisoprolol (beta 2/beta 1 = 34.7) proved to be higher than that of atenolol (8.7) and betaxolol (12.5). Propranolol (0.59) was non-selective as expected. Bisoprolol and atenolol exhibited no remarkable binding affinity to alpha 1-, alpha 2-, D1-, D2-, 5-HT2- and muscarinic cholinergic receptors at concentrations up to 1 X 10(-4) mol/l. For betaxolol binding affinities for alpha 2-, D2- and 5-HT2-receptors were found with IC50 values ranging between 2 X 10(-5) and 7 X 10(-5) mol/l. For propranolol binding affinities for alpha 1-, alpha 2-, D1-, D2- and 5-HT2-receptors were found with IC50 values ranging between 2 X 10(-6) and 9 X 10(-5) mol/l.

Adrenergic beta-Antagonists↗

[Pharmacokinetics of the beta-receptor blocker metipranolol in patients with liver cirrhosis (author's transl)].

The pharmacokinetics after oral administration of the beta-blocker metipranolol (Disorat) were investigated in 20 patients with liver cirrhosis, 8 of them with portocaval shunt. Twenty healthy persons were used as controls. Kinetic data in patients were not notably different from the normal group, in particular there was no significant difference in the mean serum concentration over 24 hours. In patients with advanced disease the only noteworthy difference was an increase of the linear rate of increase of serum concentrations. Maximal serum concentrations were found with a median of only 0,37 and 0,59 hours after intake, and in controls 0,76 hours after intake. It appears that metipranolol has no hepatic first-pass-effect and that its total clearance remains largely uninfluenced even in severe liver damage. A reduction of dosage in these diseases is thus not required from the pharmacological point of view.

Adolescent↗

[The influence of mepiprazol on monoamine metabolism in the rat CNS: demonstration of reduced norepinephrine activity and simultaneously enhanced serotonin and dopamine activities (author's transl)].

Biochemical studies of monamine turnover and neuronal reuptake indicate that mepiprazole, a novel psychotropic pyrazole derivative, decreases norepinephrine receptor activity and enhances serotonin and to a lower extent also dopamine activity in the rat CNS. It can be concluded that mepiprazole might be of value in the treatment of certain types of depression and might be helpful to alleviate side effects of L-dopa in the treatment of parkinsonism.

Animals↗